Reach Us +44-1647-403003
Cells As Delivery Vehicles For Anti-cancer Therapeutics | 5087
ISSN: 2157-7013

Journal of Cell Science & Therapy
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Cells as delivery vehicles for anti-cancer therapeutics

International Conference on Emerging Cell Therapies

Deryl Troyer

ScientificTracks Abstracts: J Cell Sci Ther

DOI: 10.4172/2157-7013.S1.002

T argeting cancer therapy specifically to the cancer site so that it does not affect healthy tissue is a major objective of current cancer research. Many different strategies for targeting therapy have been developed, including targeted drug delivery vehicles, antibody targeted therapy, protease targeted therapy, and others. There is now compelling evidence that a variety of cells can preferentially migrate to tumors to deliver anticancer molecules. Examples of such cells include bone marrow mesenchymal stem cells, neural stem cells, macrophages and umbilical cord mesenchymal cells derived from Wharton�s jelly. The latter cells have also been demonstrated to have significant intrinsic anti-tumor effects as na�ve cells against preclinical models of human cancers. These cells are attractive for cytotherapy because they do not themselves form tumors, are immunologically well tolerated, can be isolated non-invasively in large numbers. We have engineered these cells to secrete cytokines such as beta interferon to attenuate human metastatic breast cancer in mice. In addition, cells have been used as carriers for nanotherapy payloads. For example, iron/ iron oxide nanoparticles have been synthesized and loaded into RAW264.7 cells, the cells homed to peritioneal tumors, and AMF exposure resulted in a significant survival effect. Tumor-tropic cells are thus potentially valuable cytotherapy agents for targeted anti-cancer therapy.

Deryl Troyer holds DVM and PhD degrees from Kansas State University. He has served as an Assistant Professor at the University of Illinois in Urbana, Illinois, and was a visiting researcher in molecular genetics at Howard Hughes Medical Institute in Salt Lake City, Utah. He has been a professor at Kansas State University since 1986. He is a founding member of the Midwest Institute for Comparative Stem Cell Biology at KSU. He is a recipient of the international Otto Zietschman Prize in Experimental Embryology, and is a recipient of the Pfizer Award for Research Excellence

Relevant Topics